AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment ... Read More
Pharma giants bag Lynparza EMA approval for metastatic breast cancer
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency's (EMA) approval for their poly ADP-ribose polymerase ... Read More
AstraZeneca secures FDA approval for Lumoxiti in hairy cell leukemia treatment
AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti (moxetumomab pasudotox-tdfk), a CD22-directed cytotoxin for the ... Read More